Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

摘要: Despite the recent approval of third-generation therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small cell lung cancer. Conceptually, synthetic lethality holds promise identifying non-intuitive targets for tackling both acquired and intrinsic this setting. However, translating these laboratory findings into effective clinical strategies continues be elusive. Here, we provide an overview lethal approaches that have been employed study EGFR inhibitor review oncogene non-oncogene signalling mechanisms thus far unveiled by screens. We highlight potential challenges associated with progressing discoveries clinic including context dependency, plasticity, tumour heterogeneity, offer perspective on emerging network biology computational solutions exploit phenomena cancer therapy biomarker discovery. conclude presenting number tangible steps bolster our understanding fundamental advance beyond confines laboratory.